Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

997 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of androgen receptor signaling inhibitors in combination with androgen deprivation therapy for castration-sensitive metastatic prostate cancer: a retrospective analysis in a Japanese cohort.
Taga M, Sasaki T, Higashi S, Kimura S, Sawada A, Tsuchiyama K, Inoue T, Kamoto T, Terada N. Taga M, et al. Among authors: terada n. Int J Clin Oncol. 2024 Dec 18. doi: 10.1007/s10147-024-02670-5. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39692835
Feasibility of laparoscopic adrenalectomy for metastatic adrenal tumors in selected patients: a retrospective multicenter study of Japanese populations.
Goto T, Inoue T, Kobayashi T, Yamasaki T, Ishitoya S, Segawa T, Ito N, Shichiri Y, Okumura K, Okuno H, Kawakita M, Kanaoka T, Terada N, Mukai S, Sugi M, Kinoshita H, Kamoto T, Matsuda T, Ogawa O. Goto T, et al. Among authors: terada n. Int J Clin Oncol. 2020 Jan;25(1):126-134. doi: 10.1007/s10147-019-01533-8. Epub 2019 Aug 30. Int J Clin Oncol. 2020. PMID: 31471786
Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models.
Nagai T, Terada N, Fujii M, Nagata Y, Nakahara K, Mukai S, Okasho K, Kamiyama Y, Akamatsu S, Kobayashi T, Iida K, Denawa M, Hagiwara M, Inoue T, Ogawa O, Kamoto T. Nagai T, et al. Among authors: terada n. Cancer Rep (Hoboken). 2023 Feb;6(2):e1701. doi: 10.1002/cnr2.1701. Epub 2022 Aug 9. Cancer Rep (Hoboken). 2023. PMID: 36806727 Free PMC article.
A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide.
Tashiro Y, Akamatsu S, Ueno K, Kamoto T, Terada N, Hida T, Kurahashi R, Kamba T, Saito A, Lee T, Morita S, Kobayashi T. Tashiro Y, et al. Among authors: terada n. Int J Clin Oncol. 2024 Oct;29(10):1564-1573. doi: 10.1007/s10147-024-02597-x. Epub 2024 Aug 17. Int J Clin Oncol. 2024. PMID: 39153094 Free PMC article.
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: terada n. Int J Clin Oncol. 2024 Dec 17. doi: 10.1007/s10147-024-02681-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39688742
997 results